Table.

Previous Case Reports of Lymphoproliferative Disorders Following Immunosuppressive Treatment for Aplastic Anemia.

Age/sex	Dose and a type of ATG treatment	Time to appearance of initial symptoms of EBV-LPD following ATG	Time to diagnosis	Diagnosis	Peak EBV-viral loads	Treatment for LPD	Outcome	References
36/M	0.75 mg/kg/d 9 days		9 days	EBV-LPDs			Died	[13]
42/F	Rabbit, 12.5 mg/kg/d	2 weeks	2 weeks	DLBCL	4 × 106 copies/mL	Rituximab, CPM	CR	[14]
54/M	Rabbit, 3.75 mg/kg/d 5 days	26 days	26 days	EBV-LPDs	3.3 × 106 copies/106 WBC		Died	[15]
38/M	1st: Rabbit, 3.5 mg/kg/d for 5 days 2nd: Horse 3.5 mg/kg/d for 1 day	19 days	24 days	Infectious mononucleosis	30,000/150,000 cells	Cessation of CsA, Rituximab	CR	[16]
55/M	Horse	Less than a month	7 days after the appearance of initial symptoms	Diffuse atypical/clonal plasma cell hyperplasia	60,060 copies/mL	Rituximab	CR	[17]
55/M	Rabbit, 3.75 mg/kg/d for 5 days	About 3 months	84 days	Atypical lymphocytes proliferation	140 copies/106 WBC	Cessation of CsA	CR	[18]
46/F	Rabbit, 3.75 mg/kg/d for 5 days	26 days	33 days	EBV-LPDs	7.9 × 106 copies/mL	Cessation of CsA	CR	[19]
81/M	Rabbit, 3.3 mg/kg/d for 5 days	31 days	34 days	EBV-LPDs	4 × 106 copies/mL	Cessation of CsA, rituximab	Died	[20]
69/W	Rabbit	About 30 days	54 days	EBV-LPDs	3 × 105 copies/mL		Died	[21]
26/M	Rabbit, 3.75 mg/kg/d for 5 days	2 months		EBV-LPDs	120 copies/mL	Reduction of CsA, rituximab	CR	[22]
55/F	Rabbit, 3.75 mg/kg/d 5 days	28 days	36 days	EBV-LPDs	1.1 × 106 copies/106 cells	Cessation of CsA, rituximab	CR	Our case

F: female, M: male, mg/kg/d: mg/kg/day, ATG: antithymocyte globulin, EBV: Epstein - Barr virus, EBV-LPD: EBV-associated lymphoproliferative disorder, IM: infectious mononucleosis, DLBCL: diffuse large B cell lymphoma, CsA: cyclosporin A, CPM: cyclophosphamide, CR: complete response

Time to diagnosis indicates the duration from Day 1 on recent immunosuppression therapy to the appearance of the first symptom of LPD.